Jefferies reiterated their Buy rating and $25 price target on ARIAD Pharmaceuticals (NASDAQ: ARIA) after Iclusig IMS sales data indicates ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE